Patents Assigned to Argos Therapeutics, Inc.
-
Patent number: 10184108Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: December 19, 2016Date of Patent: January 22, 2019Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark Debenedette
-
Patent number: 10022731Abstract: Centrifuge vessels suitable for live cell processing include a bowl with a cap, and a tube inside the bowl extending between the cap and a lower portion of the bowl. The bottom of the bowl can have a closed annular ring surrounding a center mound. The vessels can be particularly suitable for processing low volumes of live cells for vaccines or other therapies.Type: GrantFiled: January 22, 2013Date of Patent: July 17, 2018Assignee: Argos Therapeutics, Inc.Inventors: Tamara Tatroe Monesmith, Arjun V. Caprihan, Christopher Thomas Ryan, Richard A. Grant, Ian S. Fitzpatrick, Christopher John Leigh-Lancaster
-
Patent number: 10006901Abstract: The present invention provides suppressive and/or regulative human CD4+CD25+ T cells, a method for expanding same, and the use of the suppressive and/or regulative human CD4+CD25+ T cells and the expanded T cells as regulatory agent.Type: GrantFiled: June 22, 2012Date of Patent: June 26, 2018Assignee: ARGOS THERAPEUTICS, INC.Inventors: Gerold Schuler, Detlef Dieckmann
-
Patent number: 9970068Abstract: The invention relates to improved methods and compositions for the nucleic acid amplification of one or multiple variants (strains) of Human Immunodeficiency Virus (HIV) present in a sample, and preferably in a sample from a pathogen infected individual. In particular, novel primers, methods and kits for the amplification of one or more species of HIV Rev, Gag and Nef nucleic acids are provided. The amplified HIV nucleic acid can be used to identify and/or quantitate HIV variants present in a sample. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can also be used directly as vaccines or to transfect/load antigen presenting cells. The loaded antigen presenting cells can be used as a vaccine for the treatment or prevention of HIV infection.Type: GrantFiled: May 24, 2012Date of Patent: May 15, 2018Assignee: Argos Therapeutics, Inc.Inventors: Irina Tcherepanova, Aijing Starr, Brad Lackford
-
Patent number: 9879053Abstract: This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.Type: GrantFiled: March 16, 2015Date of Patent: January 30, 2018Assignee: Argos Therapeutics, Inc.Inventors: Charles Nicolette, Irina Tcherepanova, Jason Harris, Donald Healey
-
Patent number: 9732140Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.Type: GrantFiled: June 17, 2014Date of Patent: August 15, 2017Assignee: ARGOS THERAPEUTICS, INC.Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
-
Patent number: 9638707Abstract: Processing containers include a first member having a substantially rigid body with a plurality of regions defining spaced apart workstations and a flexible barrier member sealably attached to the first member to define a closed chamber over the plurality of workstations. The flexible barrier is substantially impermeable and includes or is a manipulation tool that is sealably attached to the barrier. The manipulation tool has a first internal interface that resides in the closed chamber under the flexible barrier and a second external interface that resides outside the closed chamber. The processing containers are particularly suitable for automated processing of nucleic acids and other samples. The manipulation tool can cooperate with or include a pipette head. When the barrier is sealed, the barrier separates the contents of the container from a robotic arm or other manipulation device.Type: GrantFiled: November 21, 2016Date of Patent: May 2, 2017Assignee: Argos Therapeutics, Inc.Inventors: Simon Jonathon Spence, Richard Alexander Grant, Timothy Doyle Peele, William Samuel Hunter, Ashraf F. Abdelmoteleb, David Thomas Kneen, Robert Alister Neil, Simon Harris
-
Patent number: 9556455Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: August 29, 2014Date of Patent: January 31, 2017Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Patent number: 9527074Abstract: Processing containers include a first member having a substantially rigid body with a plurality of regions defining spaced apart workstations and a flexible barrier member sealably attached to the first member to define a closed chamber over the plurality of workstations. The flexible barrier is substantially impermeable and includes or is a manipulation tool that is sealably attached to the barrier. The manipulation tool has a first internal interface that resides in the closed chamber under the flexible barrier and a second external interface that resides outside the closed chamber. The processing containers are particularly suitable for automated processing of nucleic acids and other samples. The manipulation tool can cooperate with or include a pipette head. When the barrier is sealed, the barrier separates the contents of the container from a robotic arm or other manipulation device.Type: GrantFiled: July 21, 2016Date of Patent: December 27, 2016Assignee: Argos Therapeutics, Inc.Inventors: Simon Jonathon Spence, Richard Alexander Grant, Timothy Doyle Peele, William Samuel Hunter, Ashraf F. Abdelmoteleb, David Thomas Kneen, Robert Alister Neil, Simon Harris
-
Patent number: 9523077Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: July 15, 2013Date of Patent: December 20, 2016Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
-
Patent number: 9409178Abstract: Processing containers include a first member having a substantially rigid body with a plurality of regions defining spaced apart workstations and a flexible barrier member sealably attached to the first member to define a closed chamber over the plurality of workstations. The flexible barrier is substantially impermeable and includes or is a manipulation tool that is sealably attached to the barrier. The manipulation tool has a first internal interface that resides in the closed chamber under the flexible barrier and a second external interface that resides outside the closed chamber. The processing containers are particularly suitable for automated processing of nucleic acids and other samples. The manipulation tool can cooperate with or include a pipette head. When the barrier is sealed, the barrier separates the contents of the container from a robotic arm or other manipulation device.Type: GrantFiled: April 21, 2015Date of Patent: August 9, 2016Assignee: Argos Therapeutics, Inc.Inventors: Simon Jonathon Spence, Richard Alexander Grant, Timothy Doyle Peele, William Samuel Hunter, Ashraf F. Abdelmoteleb, David Thomas Kneen, Robert Alister Neil, Simon Harris
-
Patent number: 9102726Abstract: The present invention provides methods of using soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 proteins, specifically suited for said purpose, nucleic acids and vectors encoding said CD83 proteins, cells transformed/transfected with the nucleic acids or vectors, methods for producing said CD83 proteins, pharmaceutical compositions containing said CD83 proteins, nucleic acids or vectors, and antibodies against said soluble CD83 proteins and assay methods and kits comprising said antibodies.Type: GrantFiled: March 6, 2003Date of Patent: August 11, 2015Assignee: ARGOS THERAPEUTICS, INC.Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
-
Patent number: 9085807Abstract: This in invention relates to methods for the nucleic acid amplification of multiple variants (strains) of any pathogen present in a sample, and preferably in a sample from a pathogen infected individual. In preferred embodiments, the pathogen is a retrovirus, such as HIV. The amplified pathogen nucleic acid can be used to identify the pathogen variants present in a sample, to quantitate the pathogen present in a sample, and as a nucleic acid vaccine, or in the preparation of antigen presenting cell vaccines. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can be used to transfect/load antigen presenting cells. The loaded antigen presenting cells can then be used as a vaccine for the treatment of pathogen infection. In another embodiment, nucleic acids produced by the methods of the invention can be used directly as nucleic acid vaccines without prior loading into antigen presenting cells.Type: GrantFiled: September 14, 2005Date of Patent: July 21, 2015Assignee: Argos Therapeutics, Inc.Inventors: Charles Nicolette, Irina Tcherepanova, Jason Harris, Donald Healey
-
Patent number: 9040303Abstract: An apparatus for measuring a volume of fluid includes at least one emitter configured to project a signal toward a predetermined position of a sample container, at least one receiver configured to receive the signal after the signal interacts with the sample container and a fluid transfer device in communication with the receiver and sample container. A change in the signal received by the receiver indicates when the fluid has dropped below the predetermined position. The apparatus determines a volume of fluid that the fluid transfer device has removed from the sample container when the receiver detects that the fluid has dropped below the predetermined position.Type: GrantFiled: March 18, 2013Date of Patent: May 26, 2015Assignee: Argos Therapeutics, Inc.Inventors: Simon Jonathon Spence, Richard Alexander Grant
-
Publication number: 20150065684Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.Type: ApplicationFiled: June 17, 2014Publication date: March 5, 2015Applicant: ARGOS THERAPEUTICS, INC.Inventors: ALEXANDER STEINKASSERER, MATTHIAS LECHMANN, ELISABETH ZINSER
-
Patent number: 8822223Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: October 7, 2005Date of Patent: September 2, 2014Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Patent number: 8759505Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.Type: GrantFiled: January 21, 2011Date of Patent: June 24, 2014Assignee: Argos Therapeutics, Inc.Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
-
Patent number: 8672879Abstract: Medicament devices include a sealed medicament dose container comprising a cell based medicament that is stored at a temperature less than about ?40 degrees Celsius, then thawed into a liquid prior to administration and a medicament dose cartridge configured and sized to snugly hold the dose container therein during extraction of the liquid medicament. Related dose containers, retainers and extraction/dispensing systems are also described.Type: GrantFiled: October 13, 2006Date of Patent: March 18, 2014Assignee: Argos Therapeutics, Inc.Inventors: Richard Grant, Christopher John Leigh-Lancaster, Andrew Zipsin, Timothy Peele, Ian S. Fitzpatrick
-
Patent number: 8658771Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.Type: GrantFiled: December 19, 2012Date of Patent: February 25, 2014Assignee: Argos Therapeutics, Inc.Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen, Jan Fleckner
-
Patent number: RE46152Abstract: Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.Type: GrantFiled: August 1, 2014Date of Patent: September 20, 2016Assignee: Argos Therapeutics, Inc.Inventors: Rebecca Pogue, Tamara Monesmith, Irina Tcherepanova, Lois Dinterman